Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 209

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 209
---
uciaries to forward the proxy materials to their principals and to obtain their
authority to execute proxies and voting instructions. FutureTech will reimburse them for their reasonable expenses.

| 100 |

<div align='center'>PROPOSAL NO. 1 — THE BUSINESS
COMBINATION PROPOSAL</div>

Summary of the Merger Agreement

The summary of
the material provisions of the Merger Agreement set forth below and elsewhere in this proxy statement/prospectus is qualified in its entirety
by reference to the Merger Agreement, a copy of which is attached to this proxy statement/prospectus as Annex A, and which is incorporated
by reference in this proxy statement/prospectus. All stockholders are encouraged to read the Merger Agreement in its entirety for a more
complete description of the terms and conditions of the Business Combination.

On September 16,
2024, FutureTech entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Longevity
Biomedical, Inc., a Delaware corporation (“Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned
subsidiary of the Company (“Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller representative. The Merger
Agreement provides that the parties thereto will enter into a business combination transaction (the “Business Combination”
and together with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant to which, among
other things, (i) Longevity will consummate Target Acquisitions (as defined below) upon the terms and subject to conditions set forth
therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation of the
Target Acquisitions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company
of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of FutureTech. At the closing of the Transactions (the
“Closing”), FutureTech is expected to change its name to “Longevity Biomedical, Inc.” and FutureTech’s common
stock is expected to list on the NASDAQ Capital Market under the ticker symbol “LBIO.” The date on which the Closing actually
occurs is hereinafter referred to as the “Closing Date”.

Transaction Structure

The Merger Agreement
provides for the merger of Longevity with and into Merger Sub